INTRODUCTION
• A range of injectable medications other than insulin are now used to treat type 2 diabetes (T2D). The most commonly used non-insulin injectable medications for T2D are in the class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). 1 These treatments are often recommended as part of combination therapy when oral medication alone does not result in sufficient glycemic control 2, 3 • GLP-1 RA can be effective in lowering HbA1c, fasting blood glucose, and body weight, with a low risk of hypoglycemia. The most commonly reported adverse events are gastrointestinal side effects 1, 4, 5 • Despite similarities in efficacy and safety, GLP-1 RAs vary in their injection devices and related treatment attributes:
-The injection devices differ in a number of ways, including ease-ofuse, size, requirements for needle handling, and multiple versus single use -Some GLP-1 RAs are injected every day, 6, 7 while others are injected once weekly [8] [9] [10] -Some GLP-1 RAs require the patient to mix the medication prior to injection, 10,11 while others do not have these requirements 9 • These differences in the injection device and injection process could impact patients' quality of life and preference among treatments It's a pen, so that's easy for me to take out to identify in my bag.
RESULTS (Cont'd)

16
I do it at my house because it is too big to carry. I guess I could say I disliked it because it is so big.
Something that is not so good is the fact that you always have to refrigerate the injection liquid. It always has to be stored in the refrigerator. And if you are traveling and there is no refrigerator in the hotel room, then there will be problems.
Dosing schedule 20
The good part of that is that it does not have to be done at a certain time…I do it when I get up and then after I watched television for a while. It is very practical that one does not have to do it at the same time.
7
There is a strict time window, you must take it in the hour before you eat a large meal. That can be problematic.
Injection timing/ flexibility
19
I like that, because it gives you a lot more control, a lot more freedom of not being able to take it if you're not-you know, when it's convenient for you. 
Medication supply 7
I can see when it's just about empty. There's a tiny little bit left at the bottom. So, I know to get one now that say-usually when I see it, it's the very end-coming to the very end. I take one out of the fridge so it's ready for the next day.
5
It doesn't look any different when it's full. I took one back to the chemist thinking it was empty because I couldn't see anything.
Multiple parts 4
It makes it very convenient because when you pick it up you've got everything that you need right there in your hand.
10
One other thing that I don't like about the device is when you have to take it apart and put it together there's always that chance of getting it mixed with bacteria, jammed, or getting some infection into it…I'd prefer if I was just together.
a The number of participants reporting a positive impression of each injection device feature b The number of participants reporting a negative impression of each injection device feature
Study Design
• This was a qualitative study of patients with type 2 diabetes receiving noninsulin injectable medication. Participants took part in one-on-one concept elicitation interviews in the US, UK, and Germany. Interviews focused on experiences with devices used to administer non-insulin injectable medications. Currently, the only commercially available non-insulin injectable medications for patients in the antihyperglycemics class are the GLP-1 RAs and pramlintide
Participants
• To be eligible, participants were required to meet the following five criteria:
1. Currently residing in the US, UK, or Germany; 
Interview Procedures
• One-on-one interviews were conducted either in-person or via telephone, following a semi-structured discussion guide which was developed based on literature review and clinician interviews. The interview focused on patients' perceptions and experiences of non-insulin injection devices associated with treatment for T2D. Additional questions related to insulin injection devices were included for patients currently using both a GLP-1 RA and insulin to treat their type 2 diabetes
Qualitative Analysis
• Audio recordings of each interview were transcribed, and the qualitative data were analyzed using ATLAS.ti software. Project team members, including those who conducted the English interviews, reviewed the qualitative data obtained during the discussions and identified key themes that described important concepts raised by the participants. A coding dictionary was developed based on the content of the interview guide and concepts that emerged during the interviews
• During coding, words and phrases provided by participants were selected using the coding dictionary and grouped into key themes, attributes, concepts, and relationships 
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CONCLUSIONS
• In this multi-country qualitative study, patients reported a wide range of injection device features that influenced their perceptions of non-insulin injection devices
• Nearly all features were viewed favorably by some respondents and unfavorably by others. These differences in patient perception are likely due to differences in the treatment process and the injection device associated with each medication. For example, some patients viewed the relatively simple injection preparation as a positive feature of their injection device. However, other medications require more steps prior to injecting the medication, and patients receiving these treatments viewed injection preparation as a negative feature
• Several injection device features mentioned by these patients are assessed by previously developed patient-reported outcome (PRO) measures focusing on perceptions of insulin treatment (e.g., general ease-of-use, size of device, physical discomfort, confidence that the device delivers the correct dose) 12 • However, patients also mentioned important features of the treatment process and injection device that differentiate among non-insulin injection devices. For example, some features of GLP-1 RAs (e.g., injection preparation requirements relating to mixing the medication, variations in dose frequency, flexibility with regard to dose timing, requirements for needle handling) are not included in PRO instruments focusing on insulin treatment
• Like most qualitative research, one limitation of this study is the small sample size. The extent to which these results would generalize to a broader sample of patients with type 2 diabetes is unknown
• A patient-reported measure focusing on features important to patients treated with non-insulin injectable medications would be a useful tool for assessing patients' experiences with these treatments and associated injection devices
METHODS
RESULTS
Sample Characteristics
• Qualitative interviews were conducted with 32 patients (Table 1 )
Perceptions of Non-insulin Injection Features
• Participants reported liking and disliking a wide range of features of their injections and associated devices (Table 2) . When asked what they would like to change about non-insulin injectable devices, the most common responses were characteristics of the needle (n=8), requirements for injection preparation (n=6), or the need for multiple device parts (n=6) You just put the needle on top, screw the needle on, and you set the dial, and you press the button. So, it's very easy.
14 When you're mixing them you have to be careful how you mix it…I wish I didn't have to go through the stages of mixing it, and shaking the device, and making sure it's well diluted. It's a waste of time.
Injection comfort 28
It doesn't hurt to do, so you just stick it in, push it in and that's it. 11
It was more of a discomfort issue, because you're really trying to figure what's going to be the right angle to inject it Needle (including disposing, attaching/ removing, and size of the needle) 28 I like that I'm not having to put the needle in myself. I'm not having to really look at the needle. I like that I don't have to make sure that I have the needles available. It's always in the device.
18
I think I don't like the fact that after you mix it up, you now have to screw the needle on top of it… I feel everything should come together.
Dose delivery confidence/con firmation
28
I am [confident] because it's premeasured and all I have to do is make sure that it's mixed and inject.
9
I wonder sometimes if it all goes in because when I pull it out sometimes there will be liquid at the end of it.
Injection frequency 25
I do not have to inject…every day, but only once a week. I think that is just great.
6
I would like it to be once a day, but is it possible, I don't know. But once you've done it you wouldn't forget about it, that would be it, you wouldn't have to think about it for the rest of the day.
Selecting dose 25
The pen does it itself…I like that. It makes it easy. I wouldn't like to select how much I needed each day… 4
There is a display there… This grid is not very accurate…the setting selector should be a bit more precise.
Disposal
24
Everything is fine on the way you take it apart and dispose of it. 5
If I'm on the street, I can't walk around with a sharp bin or anything like that, so I have to find somewhere safe enough… I've got to make sure that …I've not left it anywhere that anybody could go and touch it. Time requirements 24 Yes, it's very quick and easy. 4 Well, like I said, it's time consuming.
Size 23 It's compact in size, you can carry it in your pocket. 11
It's not discreet, it's a very large device…I always do it at home, I would never do it out in public because of the size.
Injection site 23
I put it in my arm. Put it here [participant demonstrates], put it in your belly…I can put it anywhere. No, it's never been a problem.
7
That takes a little getting used to…Because you can only do it in certain areas of your body…The part that bothers me is that it can get very sensitive so you have to find a spot that's not sensitive.
Design/ appearance 22
There's bright colors on there as well, so obviously it's easy to notice or easy to spot. I know it's separate from my other medication.
2
Just the color. I dislike it, but only because it's a bit vivid. If it was plain white it wouldn't be so obvious or, you know.
Storage 22
You have to store them in the fridge before you use them. But once you use the first dose, that you just put it in the cupboard, so. So there's nothing problematic about that? No, not in the least.
15
The box takes up a little bit of room in my refrigerator, I would rather it be a smaller box…
• Therefore, this qualitative study was designed to understand patients' experiences with non-insulin injection delivery systems
